NCT03645499 - An Open-Label Study to Assess Safety | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2018

Primary Completion Date

October 24, 2019

Study Completion Date

January 7, 2020

Conditions

Plaque Psoriasis

Interventions

DRUG

Topical TA-102 A

applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks

DRUG

Topical TA-102 B

applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks

DRUG

Topical TA-102 C

applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks

DRUG

Topical TA-102 D

applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks

DRUG

Topical TA-102 E

applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks

Trial Locations (1)

Catawba Research, LLC, Charlotte

All Listed Sponsors

lead

Sun Pharmaceutical Industries, Inc.

INDUSTRY